494 related articles for article (PubMed ID: 33299645)
21. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
22. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
23. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma.
Li GX; Ding ZY; Wang YW; Liu TT; Chen WX; Wu JJ; Xu WQ; Zhu P; Zhang BX
J Cell Physiol; 2019 Jul; 234(7):11942-11950. PubMed ID: 30536816
[TBL] [Abstract][Full Text] [Related]
24. Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model.
Zhang Y; Zeng F; Zeng M; Han X; Cai L; Zhang J; Weng J; Gao Y
Int J Biol Sci; 2021; 17(13):3554-3572. PubMed ID: 34512165
[No Abstract] [Full Text] [Related]
25. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
27. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
Yu ZL; Zhu ZM
Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
[TBL] [Abstract][Full Text] [Related]
29. The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity.
Zhao JW; Zhao WY; Cui XH; Xing L; Shi JC; Yu L
Clin Transl Oncol; 2024 Feb; 26(2):496-514. PubMed ID: 37407805
[TBL] [Abstract][Full Text] [Related]
30. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
[TBL] [Abstract][Full Text] [Related]
31. M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy.
Zhao K; Wei B; Zhang Y; Shi W; Zhang G; Wang Z
Front Pharmacol; 2022; 13():1052177. PubMed ID: 36438800
[No Abstract] [Full Text] [Related]
32. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
33. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
Front Genet; 2021; 12():752025. PubMed ID: 35046996
[No Abstract] [Full Text] [Related]
34. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
Front Immunol; 2022; 13():888650. PubMed ID: 35572541
[TBL] [Abstract][Full Text] [Related]
35. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
Qin S; Mao Y; Chen X; Xiao J; Qin Y; Zhao L
Int J Biol Sci; 2021; 17(12):3059-3079. PubMed ID: 34421350
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
37. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
38. m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment.
Liu F; Yu X; He G
J Oncol; 2021; 2021():9987376. PubMed ID: 34745261
[TBL] [Abstract][Full Text] [Related]
39. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
40. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
